Cancer Drugs
Tagrisso
Also known as: Osimertinib, EGFR TKI
Definition
Osimertinib, a third-generation EGFR TKI effective against sensitizing and T790M resistance mutations in NSCLC.
Detailed Explanation
Tagrisso is standard first-line therapy for EGFR-mutated NSCLC and is used as adjuvant therapy post-surgery. It penetrates the CNS for brain metastases.